A. Tomiyama

发表

Intracellular cyclic adenosine 3', 5'-monophosphate and relaxing effects of isoprenaline and papaverine on smooth muscle of intestine.

M. Uchida, K. Takagi, I. Takayanagi, 1972, Japanese journal of pharmacology.

Synthesis and pharmacological activity of the metabolites of Pratosartan.

A. Tomiyama, M. Sonegawa, T. Tomiyama, 2006, Chemical & pharmaceutical bulletin.

Effects of temperature and spasmolytic agents on the rate of relaxation of intestinal smooth muscle.

L. Hurwitz, A. Tomiyama, 1975, Proceedings of the Western Pharmacology Society.

Relaxing action of synthetic antispasmodics on the intestinal smooth muscle of guinea pig.

M. Uchida, K. Takagi, I. Takayanagi, 1973, Japanese journal of pharmacology.

Beta-adrenergic blocking action of ruthenium red.

K. Takagi, I. Takayanagi, A. Tomiyama, 1973, Japanese journal of pharmacology.

Relaxation of intestinal smooth muscle and calcium movements

K. Takagi, I. Takayanagi, A. Tomiyama, 1973, The Journal of pharmacy and pharmacology.

Effects of topical application of KT1-32 on transmucosal potential difference and acid secretion in the rat stomach.

K. Takeuchi, S. Okabe, A. Tomiyama, 1990, Japanese journal of pharmacology.

Therapeutic effect of egualen sodium (KT1-32), a new antiulcer agent, on chronic gastritis induced by sodium taurocholate in rats

M. Matsumoto, A. Tomiyama, K. Kosakai, 1996, Journal of Gastroenterology.

Thromboxane A2 antagonistic action of a new anti-ulcer agent, azuletil sodium (KT1-32).

S. Shibata, N. Satake, A. Tomiyama, 1989, Scandinavian journal of gastroenterology. Supplement.

Relationships between Ca2+ uptake by a microsomal fraction of guinea-pig taenia caecum and its relaxation.

K. Takagi, I. Takayanagi, A. Tomiyama, 1975, Biochemical pharmacology.

Mode of vasorelaxing action of 5-[3-[[2-(3,4-dimethoxyphenyl)-ethyl]amino]-1-oxopropyl]-2,3,4,5- tetrahydro-1,5-benzothiazepine fumarate (KT-362), a new intracellular calcium antagonist.

S. Ueda, S. Shibata, N. Satake, 1987, The Journal of pharmacology and experimental therapeutics.

The inhibitory effect of KT3-671, a nonpeptide angiotensin-receptor antagonist, on rabbit and rat isolate vascular smooth muscles: a possible involvement of K(ATP) channels.

S. Shibata, N. Satake, A. Tomiyama, 2000, Journal of cardiovascular pharmacology.

Effect of repeated administration of KT3-671, a nonpeptide AT1 receptor antagonist, on diurnal variation in blood pressure, heart rate, and locomotor activity in stroke-prone spontaneously hypertensive rats as determined by radiotelemetry.

K. Kawashima, H. Amano, T. Fujii, 1996, Journal of cardiovascular pharmacology.

Pharmacologic Properties of KT2–962 (6‐Isopropyl‐3‐[4‐(p‐Chlorobenzenesulfonylamino)‐Butyl]‐ Azulene‐1‐Sulfonic Acid Sodium Salt); a New TXA2/Prostaglandin Endoperoxide Receptor Antagonist

S. Shibata, Qin Zhou, N. Satake, 1993, Journal of cardiovascular pharmacology.

Pharmacological Properties of KT3–671, a Novel Nonpeptide Angiotensin II Receptor Antagonist

Y. Ohkura, A. Tomiyama, K. Kosakai, 1995, Journal of cardiovascular pharmacology.

Antihypertensive activity and pharmacokinetics of KD3-671, a nonpeptide AT1-receptor antagonist, in renal hypertensive dogs.

H. Kato, Y. Takata, A. Tomiyama, 1998, Journal of cardiovascular pharmacology.

Antihypertensive effect of chronic KT3-671, a structurally new nonpeptide angiotensin AT1-receptor antagonist, in stroke-prone spontaneously hypertensive rats.

K. Kawashima, H. Amano, T. Fujii, 1995, Japanese journal of pharmacology.